We have also introduced tumor-homing immunomodulatory ACPs that are not only able to target tumor-cell membrane and intracellular apoptotic/necrotic cascades but also affect TME, such as angiogenesis, and TIME, such as APC induction. Here, APC is linked to neoplasm.